NR3C1 and COVID-19: To validate our framework, we first applied it to four clinically relevant drug–target pairs associated with COVID-19: Nirmatrelvir–MPro, Remdesivir–RdRp, Baricitinib–JAK2, and Dexamethasone–glucocorticoid receptor.